ClinicalTrials.gg
CompletedNCT04824781Updated May 19, 2022

Recovery From Paranoia: a Qualitative Exploration

An observational study in Paranoia and Persecutory Delusion, sponsored by University of Oxford. Completed at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2022-05-19.

Sponsored by University of Oxford · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
15
Ages
16 Years and older
Sex
All
01

Study summary

Paranoia, the experience of undue or excessive mistrust, exists on a continuum which includes suspicious thoughts, ideas of reference, and persecutory delusions. Persecutory delusions refers to strong unfounded fears that others intend harm. These fears are very common. They affect around 70% of patients with schizophrenia. They can be distressing and make day-to-day tasks difficult. However, current treatments are limited and a significant proportion of people do not benefit sufficiently. Therefore, improvements in treatment are needed. A better understanding of the experience of recovery from paranoia will help inform theoretical understanding and treatment development. Currently we do not fully understand what causes paranoia to occur, persist, or end. As such, it is critical to understand the experiences of those who have recovered, in particular what elements encourage recovery. Therefore, the aim of this study is to gain a first-person perspective on how people recover from paranoia and what psychological processes are important for recovery from paranoia. Using a qualitative approach appropriate for exploratory research, semi-structured interviews will be conducted with 12-15 patients who have recovered from paranoia. Interviews will be analysed using interpretative phenomenological analysis, a qualitative research approach which aims to provide insight on how an individual, in a particular situation, makes sense of their experience.

02

Conditions studied

  • Paranoia
  • Persecutory Delusion

Browse trials for

Keywords

  • Paranoia
  • Persecutory delusions
  • Recovery
  • NHS
  • Qualitative
  • Interpretative phenomenological analysis
03

In context

Paranoid Disorders

20 studies on the registry are indexed under Paranoid Disorders; 7 are open to participants now.

Browse Paranoid Disorders studies →

Lead sponsor

University of Oxford is the lead sponsor of 812 studies on the registry; 119 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

A sample of approximately 15 patients who have recovered from paranoia will be recruited. Participants will be recruited according to the inclusion and exclusion criteria adumbrated below.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has recovered from the paranoia. This is defined as: A.) conviction in persecution beliefs is rated as less than 10% and B.) not experiencing significant distress related to paranoia and C.) currently scoring outside the clinical range of the revised Green et al., Paranoid Thoughts Scale (R-GPTS; Freeman, 2019);
  • Participants should have had experiences of paranoia in the context of non-affective psychosis. This will be determined by participant's agreement that they previously had the sort of thoughts listed in the revised Green et al. Paranoid Thoughts Scale (R-GPTS; Freeman, 2019);
  • Participant is currently a patient of Oxford Health NHS Foundation Trust;
  • Participant is willing and able to give for participation in the study;
  • Aged 16 years or above;
  • Participant has sufficient English language skills to participate in the interview.

Exclusion criteria

Exclusion Criteria:

The following exclusion criteria will apply based on concerns regarding risk and capacity to consent:

  • Currently experiencing acute psychiatric symptoms which preclude ability to participate in a sustained interview;
  • Diagnosis of a moderate to severe intellectual disability;
  • High levels of associated risk to self or to others e.g. actively suicidal;
  • Primary diagnosis of alcohol or drug misuse; personality disorder; significant forensic history;
  • At the time of recruitment COVID-19 restrictions do not permit face-to-face interviews and the participant is not willing or able to conduct the interview remotely via video call.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
15 participants (actual)
Patient registry
No

Interventions

  • OtherQualitative interview

    Participants will be interviewed about their experiences of recovery from paranoia.

06

What researchers measure

Primary outcomes

  1. Qualitative interview accounts

    Semi-structured interpretative phenomenological analysis (IPA) interviews will be used.

    Time frame: March 2021-March 2022

07

Study locations

1 site
  • Oxford Health NHS Foundation Trust
    Oxford, Oxfordshire OX3 7JX, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jul 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2021
First posted
Apr 1, 2021
StartActual
Jun 9, 2021
Primary completionActual
Jul 27, 2021
CompletionActual
Feb 16, 2022
Last update
May 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04824781
Responsible party
Sponsor
First posted
Apr 1, 2021
Start date
Jun 9, 2021
Primary completion
Jul 27, 2021
Completion
Feb 16, 2022
Last update
May 19, 2022

Study contacts

Dr Felicity Waite, DClinPsy, BSc (Hons)
study director · University of Oxford

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion